Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $7.25.

A number of analysts have issued reports on MIST shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Tuesday, July 14th. Zacks Research upgraded Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Raymond James Financial initiated coverage on Milestone Pharmaceuticals in a research report on Friday, April 10th. They issued a “strong-buy” rating and a $6.00 price objective for the company. Wells Fargo & Company lowered their price objective on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating on the stock in a research note on Thursday, May 14th. Finally, Wall Street Zen lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Sunday, May 17th.

Institutional Trading of Milestone Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of MIST. Bay Rivers Group increased its holdings in shares of Milestone Pharmaceuticals by 55.9% during the 2nd quarter. Bay Rivers Group now owns 46,633 shares of the company’s stock worth $62,000 after purchasing an additional 16,722 shares during the period. Seven Fleet Capital Management LP bought a new stake in shares of Milestone Pharmaceuticals in the first quarter valued at about $397,000. Renaissance Technologies LLC bought a new stake in shares of Milestone Pharmaceuticals in the first quarter valued at about $154,000. Welch & Forbes LLC acquired a new stake in Milestone Pharmaceuticals during the first quarter worth about $30,000. Finally, TRU Independence Asset Management 2 LLC acquired a new stake in Milestone Pharmaceuticals during the fourth quarter worth about $202,000. 86.18% of the stock is currently owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Trading Down 3.5%

Shares of NASDAQ:MIST opened at $1.11 on Friday. The company has a market cap of $138.19 million, a P/E ratio of -1.63 and a beta of 0.97. The stock’s 50-day moving average is $1.27 and its 200-day moving average is $1.58. Milestone Pharmaceuticals has a 52-week low of $1.00 and a 52-week high of $3.06. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.09 and a current ratio of 9.18.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26). The firm had revenue of $0.24 million during the quarter, compared to analyst estimates of $30.11 million. Equities research analysts predict that Milestone Pharmaceuticals will post -0.83 earnings per share for the current year.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.